Viral Vitalism

Medicine

Alcohol Use Disorder

Research-backed explainers on alcohol use disorder, craving, reward biology, clinical trials, GLP-1 research, and treatment questions.

1 published articleBuilding this topic
MedicineEarly evidenceGLP-1

GLP-1s, Dopamine, and Addiction: The Substance Use Signal

GLP-1 medications may do more than reduce appetite for food. Early clinical trials, real-world data, and preclinical research suggest they may also affect craving, reward, alcohol intake, and substance-use patterns - but the science is still developing.

16 min readRead->

Related research

Semaglutide AUD Phase 2: Once-Weekly Semaglutide in Adults With Alcohol Use DisorderSemaglutide AUD + Obesity: Once-weekly semaglutide versus placebo in patients with alcohol use disorder and comorbid obesityExenatide AUD: Exenatide once weekly for alcohol use disorder investigated in a randomized, placebo-controlled clinical trialSemaglutide AUD EHR: Associations of semaglutide with incidence and recurrence of alcohol use disorder in real-world population

Useful source library entries

Once-Weekly Semaglutide in Adults With Alcohol Use DisorderSemaglutide for Alcohol Use DisorderOnce-weekly semaglutide versus placebo in patients with alcohol use disorder and comorbid obesityGLP-1 plus therapy can reduce heavy drinkingExenatide once weekly for alcohol use disorder investigated in a randomized, placebo-controlled clinical trial

Related topics

MedicineGLP-1Regenerative MedicineSemaglutideTirzepatideWegovy

Vital Signals

Get the weekly health signal without the wellness fog.

A clean weekly brief covering longevity science, fitness, nutrition, medicine, health culture, and the claims worth questioning.

No spam. No miracle claims. Just better health signal.

By subscribing, you agree to receive email from Viral Vitalism. Unsubscribe anytime. See our Privacy Policy.